In this study, we identified a non‐canonical Raf‐1/p70S6K signalling pathway in NSCLC where Raf‐1 targets p70S6K as its downstream effector to regulate NSCLC tumour growth via sustaining proliferation, inhibiting apoptosis and promoting cell cycle progression (Figure 6). This evidence concerns the gene RAF1 and neoplasm.